drugset / Trial / NCT03880357

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

NCT03880357

Phase 1 Completed 485 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of scalp psoriasis.

Timeline

Start
2018-10-22
Primary completion
2019-03-15
Completion
2019-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Betamethasone Other / unclassified Topical
Comparator Calcipotriol Small molecule 0.005 % Topical
Comparator betamethasone dipropionate Small molecule 0.064 % Topical

Indications